Skip to main content
Delfa

← Trials/Trial dossier/NCT00244322

CompletedPhase 2

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease

Asset

Semagacestat

Listed sites

6

Recruiting sites

-

Enrollment

45

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•Study partner/caregiver required

Primary endpoint

•Safety and tolerability

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID9097
SecondaryH6L-MC-LFAJ
NCT IDNCT00244322

Timeline

Milestones

Study start2005-10 (month precision)
Study first posted2005-10-26estimated
Study completion2006-12actual (month precision)
Last update posted2007-05-28estimated

Assets

Drug assets

Semagacestat

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•At least 50 years of age and diagnosed with mild to moderate probable Alzheimer's disease
•Fluent in reading and speaking English and have a reliable study partner (caregiver) (someone who is in frequent contact and can make sure study medication is being taken correctly).
•If currently treated with certain drugs for Alzheimer's disease, doses must be the same for at least the last 2 months prior to starting study drug

Exclusion criteria

•Cannot be currently using or require MAOI antidepressants (such as selegiline or Eldepryl(R)), antipsychotics, benzodiazepines, calcium channel blockers for heart disease, and propanolol.
•Cannot have a clinically significant and/or uncontrolled condition or other significant disease, including a condition requiring treatment with warfarin or heparin; or have had or currently have a peptic ulcer, reflux disease, or gastrointestinal (GI) bleeding.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
3
Memory
1
Safety / tolerability / PK
1

Memory

1 endpoint
Secondary/protocol endpoint

Evaluate changes in thinking and memory

descriptive

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Safety and tolerability

descriptive

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Determine levels of peptides in blood and spinal fluid that might relate to Alzheimer's disease

descriptive

Secondary/protocol endpoint/low confidence

Evaluate changes in daily living activities

descriptive

Secondary/protocol endpoint/low confidence

Determine levels of study drug in blood and spinal fluid

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.